NAT10 and esophageal squamous cell carcinoma: G‐749 became our focus of this study (Figure 5B), because it satisfied all the following criteria: 1) it exhibited a significant anti‐invasive effect on ESCC cells in a dose‐dependent manner (Figure 5C; Figure S76A, Supporting Information); 2) it demonstrated a remarkable effect on the markers of autophagy and lysosomal acidification compared to other candidate compounds (Figure S7B,C, Supporting Information); 3) it could suppress the protein expression of NAT10 in a dose‐dependent manner (Figure 5D); 4) it protected the protein degradation of NAT10 (Figure 5E).